INTERNATIONAL STANDARD

ISO 18310-2

First edition 2021-05

Measurement and prediction of the ambient dose equivalent from patients receiving iodine 131 administration after thyroid ablation —

Part 2:

External effective dose of the caregivers after release from the hospital

Mesurage et prévision de l'équivalent de dose ambiant de patients bénéficiant d'un traitement par iode 131 après ablation de la thyroïde —

Partie 2: Dose externe efficace des proches après sortie *d'hospitalisation*

Reference number ISO 18310-2:2021(E)



© ISO 2021

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office CP 401 • Ch. de Blandonnet 8 CH-1214 Vernier, Geneva Phone: +41 22 749 01 11 Email: copyright@iso.org Website: www.iso.org

Published in Switzerland

Contents

Forew	ord	iv
Introd	luction	v
1	Scope	
2	Normative references	
3	Terms and definitions	2
4	General requirements for the release of patient with caregiver4.1Discharge criteria4.2Management procedures of the patient receiving ¹³¹ I administration4.3Release from the medical facility4.4Responsibility of the designated expert	3 3 3
5	Measurement of the effective dose to the caregiver5.15.2Specifications of the personal dosimeter5.3Measurement of the effective dose to the caregiver	4 4
6	Quality control	5
7	Uncertainty	
Annex	A (informative) Examples of written instructions to be presented to patients or their legal guardians before leaving the hospital after treatment with radioiodine	6
Annex	B (informative) Experimental application to this document: measurement and prediction of the effective dose to the caregiver in the vicinity of the patients receiving radioiodine 131 administration after thyroid ablation	Q
Rihlio	graphy	
0.100.0		

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation on the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see the following URL: www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 85, *Nuclear energy, nuclear technologies, and radiological protection*, Subcommittee SC 2, *Radiological protection*.

A list of all the parts in the ISO 18310 series can be found on the ISO website

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at <u>www.iso.org/members.html</u>.

Introduction

ISO 18310 series addresses methods and procedures for measuring ambient dose equivalent from patients administered ¹³¹I for thyroid cancer therapy.

Thyroid cancer can be treated by administering radioiodine with the remnants after surgery, because radioiodine selectively accumulates in thyroid tissue to irradiate and kill the cancerous cells. Thyroid cancers are small and are not likely to develop into aggressive malignancies. Earlier diagnosis and treatment can remove these cancers at a time when they are not likely to have spread beyond the thyroid gland.

There are two common practices for the treatment of thyroid cancer: One is a radioiodine administration without thyroid resection. The other is administration after thyroid resection. In recent years, the radioiodine administration after surgery has become more common as radioiodine selectively accumulates in thyroid tissue to irradiate and kill the cancerous cells.

The most commonly used radionuclide for the treatment is ¹³¹I. ¹³¹I is a radioisotope that emits gamma rays following beta decay. The primary emissions of ¹³¹I decay are thus electrons with a maximal energy of 606 keV (89 % abundance, others 248 keV – 807 keV) and 364 keV gamma rays (81 % abundance, others 723 keV). Since the abundance of 364 keV gamma-ray is much greater than other gamma-ray energies, the main contribution to the ambient dose equivalent is from 364 keV gamma-ray. Its radiological half-life is 8,02 d. The iodine is administered orally and is absorbed in the gastrointestinal tract. Most iodine subsequently travels through the blood and is available in the circulation for uptake by the thyroid gland and urinary excretion; the remainder is excreted in faeces, sweat, saliva and breast milk in organic form.^[1] For patients who have had their thyroid removed, the retention time in the body is shorter than that of patients who have not had their thyroid removed.

Patients who receive radioiodine treatment for thyroid cancer emit radiation and represent a potential hazard to other individuals. Critical groups among the public are fellow travellers on the patient's trip back home from the hospital, members of the patient's family, close friends, caregivers and comforters.

For the purpose of the ISO 18310 series, this document focus on the determination of the effective dose to the caregiver in the vicinity of the patient treated with radioiodine. It is based on the estimation of the effective dose using a personal dosimeter worn by the caregiver. The uncertainty of the effective dose is also provided.

this document is a preview demendence of the document is a preview demendence of the document of the document

Measurement and prediction of the ambient dose equivalent from patients receiving iodine 131 administration after thyroid ablation —

Part 2:

External effective dose of the caregivers after release from the hospital

1 Scope

This document addresses the measurement methods, procedures and uncertainty estimation for the measurement, using a personal dosimeter, of the effective dose to the caregiver in the vicinity of the patient treated with radioiodine to ablate the thyroid.

The general requirements for the patient and caregiver and a guidance (see <u>Annex A</u>) for designated expert on instructing caregivers of discharged patients is considered to effectively measure the effective dose to the caregiver in the vicinity of the patient.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 4037-1, Radiological protection — X and gamma reference radiation for calibrating dosemeters and doserate meters and for determining their response as a function of photon energy — Part 1: Radiation characteristics and production methods

ISO 4037-2, Radiological protection — X and gamma reference radiation for calibrating dosemeters and doserate meters and for determining their response as a function of photon energy — Part 2: Dosimetry for radiation protection over the energy ranges from 8 keV to 1,3 MeV and 4 MeV to 9 MeV

ISO 4037-3, Radiological protection — X and gamma reference radiation for calibrating dosemeters and doserate meters and for determining their response as a function of photon energy — Part 3: Calibration of area and personal dosemeters and the measurement of their response as a function of energy and angle of incidence

ISO 4037-4, Radiological protection — X and gamma reference radiation for calibrating dosemeters and doserate meters and for determining their response as a function of photon energy — Part 4: Calibration of area and personal dosemeters in low energy X reference radiation fields

ISO 18310-1, Measurement and prediction of the ambient dose equivalent from patients receiving iodine 131 administration after thyroid ablation — Part 1: During the hospitalization

ISO 29661, Reference radiation fields for radiation protection — Definitions and fundamental concepts

ISO/IEC Guide 99, International vocabulary of metrology — Basic and general concepts and associated terms (VIM)